DK1414496T3 - Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid - Google Patents

Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid

Info

Publication number
DK1414496T3
DK1414496T3 DK02766983.7T DK02766983T DK1414496T3 DK 1414496 T3 DK1414496 T3 DK 1414496T3 DK 02766983 T DK02766983 T DK 02766983T DK 1414496 T3 DK1414496 T3 DK 1414496T3
Authority
DK
Denmark
Prior art keywords
pravastatin
pharmaceutical composition
ppar
alpha
combination
Prior art date
Application number
DK02766983.7T
Other languages
English (en)
Inventor
Francis Vanderbist
Arthur Deboeck
Philippe Baudier
Antonio Sereno
Original Assignee
Galephar M F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar M F filed Critical Galephar M F
Priority claimed from PCT/BE2002/000135 external-priority patent/WO2003013608A1/en
Application granted granted Critical
Publication of DK1414496T3 publication Critical patent/DK1414496T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02766983.7T 2001-08-07 2002-08-07 Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid DK1414496T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE0100133 2001-08-07
PCT/BE2001/000147 WO2003013607A1 (en) 2001-08-07 2001-09-07 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
PCT/BE2002/000135 WO2003013608A1 (en) 2001-08-07 2002-08-07 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR

Publications (1)

Publication Number Publication Date
DK1414496T3 true DK1414496T3 (da) 2011-01-24

Family

ID=3862570

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02766983.7T DK1414496T3 (da) 2001-08-07 2002-08-07 Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid

Country Status (7)

Country Link
US (2) US20070092567A1 (da)
AT (2) ATE322896T1 (da)
DE (1) DE60238059D1 (da)
DK (1) DK1414496T3 (da)
ES (1) ES2352189T3 (da)
PT (1) PT1414496E (da)
WO (2) WO2003013607A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663174A1 (en) * 2003-08-05 2006-06-07 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent
DE60331963D1 (de) * 2003-08-06 2010-05-12 Galephar M F Stabile pharmazeutische zubereitungen zur kontrollierten freisetzung von fenofibrat and pravastatin
CN103040798A (zh) * 2011-11-08 2013-04-17 深圳信立泰药业股份有限公司 一种苯扎贝特缓释药物组合物
JP6149865B2 (ja) 2011-12-14 2017-06-21 エルテーエス ローマン テラピー−ジステーメ アーゲー フェノフィブラートのための強化された溶解速度を備えたウェーハ及びカプセル製剤
KR102501636B1 (ko) * 2021-12-07 2023-02-21 에이스바이오팜 주식회사 페노피브린산을 포함하는 경구용 정제 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2039763A1 (en) * 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
CA2048395A1 (en) * 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
BE1011363A3 (fr) * 1997-09-11 1999-08-03 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee.
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6368620B2 (en) * 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
AU7984200A (en) * 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
CZ20023826A3 (cs) * 2000-06-09 2003-04-16 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
WO2003013607A1 (en) 2003-02-20
US20070092567A1 (en) 2007-04-26
ATE485058T1 (de) 2010-11-15
DE60238059D1 (de) 2010-12-02
ATE322896T1 (de) 2006-04-15
WO2003013501A1 (en) 2003-02-20
PT1414496E (pt) 2012-04-20
ES2352189T3 (es) 2011-02-16
US20150037414A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
DE60127457D1 (de) Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
PT797991E (pt) Formulacao com libertacao prolongada contendo venlafaxina
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ID30205A (id) Asam-asam lemak esensial dalam pencegahan kejadian-kejadian kardiovaskular
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
TR200001982T2 (tr) Farmasötik vurulu salınımlı oral dozaj şekli.
ATE236627T1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
DK0656776T3 (da) Flerlagstabletter med reguleret frigivelse indeholdende både naproxen og naproxen-natriumsalt
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
MX9205432A (es) Compuestos inhibidores de la biosintesis de leucotrienos y composicion farmaceutica que los contiene.
IS2749B (is) Ný tegund af lyfjablöndu
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
ATE317280T1 (de) Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
DE60008127D1 (de) Diät mit hohem lipidgehalt
NZ522242A (en) Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
DK1651194T3 (da) Stabile farmaceutiske sammensætninger med kontrolleret frigivelse, hvilke indeholder fenofibrat og pravastatin
DK1414496T3 (da) Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid
NO996468L (no) Anvendelse av gaba-analoger slik som gabapentin i fremstillingen av et medikament for behandling av betennelsessykdommer
DK0667155T3 (da) Tabletter med thioctsyre med bestemt kornstørrelse
DK1409449T3 (da) Alpha-ketoglutarater af aktive ingredienser og sammensætninger omfattende disse
ITRM920222A0 (it) Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
ATE199495T1 (de) Pharmazeutische zubereitung zur direktverpressung
ATE258435T1 (de) Pinolensäure gegen diabetes